Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
NCT00031083
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Glioblastoma Multiforme
Anaplastic Astrocytoma
Oligoastrocytoma, Mixed
Gliosarcoma
Interventions
GENETIC:
Interferon-beta
Sponsor
Biogen